Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients May Benefit from Sprycel/Chemotherapy Combination (07/28/2010)
The initial report of a Phase II study evaluating Sprycel® (dasatinib) combined with chemotherapy for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) indicates that 94% of patients achieve a complete remission. These findings were recently published in the journal Blood.

Study Evaluates Anthracycline-related Heart Problems in Childhood Cancer Survivors (05/28/2010)
Children with particular variants of drug-metabolizing genes may be more likely than other children to develop heart problems after low doses of anthracycline chemotherapy. The results of this study will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.

Mylotarg Withdrawn from Market in United States (06/23/2010)
Mylotarg® (gemtuzumab ozogamicin), a drug used for the treatment of acute myeloid leukemia (AML), will be withdrawn from the U.S. market following a recent clinical trial that raised new concerns about safety and failed to demonstrate clinical benefit.

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.

Survivors of Some Childhood Cancers May Face Cognitive Impairment (05/18/2010)
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal of the National Cancer Institute.

Tasigna Approved for Initial Treatment of Chronic Myeloid Leukemia (06/22/2010)
The U.S. Food and Drug Administration has expanded the approval of Tasigna® (nilotinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Sprycel May Be More Effective than Gleevec for Initial Treatment of CML (06/07/2010)
In the initial treatment of chronic myeloid leukemia (CML), Sprycel® (dasatinib) produces higher response rates than Gleevec® (imatinib). These results were presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Cell Phone Towers and Childhood Cancer Risk (07/01/2010)
Recent findings indicate that children who are exposed to radiofrequency fields from cell phone towers before birth do not have an increased risk of early childhood cancer. This study was published in the British Medical Journal.